Country: United States
Language: English
Source: NLM (National Library of Medicine)
TERBUTALINE SULFATE (UNII: 576PU70Y8E) (TERBUTALINE - UNII:N8ONU3L3PG)
UBI Pharma Inc.
SUBCUTANEOUS
PRESCRIPTION DRUG
Terbutaline sulfate injection is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. - Prolonged Tocolysis Terbutaline sulfate has not been approved for and should not be used for prolonged tocolysis (beyond 48-72 hours). In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. [See Boxed Warning: Prolonged Tocolysis.] - Hypersensitivity Terbutaline sulfate injection is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product.
Terbutaline Sulfate Injection USP; 1 mg/mL, is supplied at a volume of 1 mL contained in a 2 mL clear glass vial. Each vial contains 1 mg of terbutaline sulfate per 1 mL of solution; 0.25 mL of solution will provide the usual clinical dose of 0.25 mg. Vials are expiration-dated. NDC 72843-101-10; Carton of 10 vials. Store at 20° to 25°C (68° to 77°F). See USP controlled room temperature. Protect from light by storing vials in original carton until dispensed. Do not use if solution is discolored. Discard unused portion after single patient use. Manufactured by: UBI Pharma Inc. Hsinchu, 30351 Taiwan Manufactured for: United Biomedical Inc. Hauppauge, NY 11788 Revised:01/2019
Abbreviated New Drug Application
TERBUTALINE SULFATE- TERBUTALINE SULFATE INJECTION UBI PHARMA INC. ---------- TERBUTALINE SULFATE INJECTION USP Vials A sterile aqueous solution for subcutaneous injection Rx Only Prescribing Information WARNING: PROLONGED TOCOLYSIS Terbutaline Sulfate has not been approved for and should not be used for prolonged tocolysis (beyond 48-72 hours). In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [See CONTRAINDICATIONS, _ Prolonged_ _Tocolysis_.] DESCRIPTION Terbutaline sulfate USP, the active ingredient of terbutaline sulfate injection, is a beta-adrenergic agonist bronchodilator available as a sterile, nonpyrogenic, aqueous solution in vials, for subcutaneous administration. Each milliliter of solution contains 1 mg of terbutaline sulfate USP (0.82 mg of the free base), sodium chloride for isotonicity, and hydrochloric acid for adjustment to a target pH of 4. Terbutaline sulfate is (±)-α-[( _tert_-butylamino)methyl]-3,5-dihydroxybenzyl alcohol sulfate (2:1) (salt). The molecular formula is (C H N0 ) •H SO and the structural formula is: Terbutaline sulfate USP is a white to gray-white crystalline powder. It is odorless or has a faint odor of acetic acid. It is soluble in water and in 0.1N hydrochloric acid, slightly soluble in methanol, and insoluble in chloroform. Its molecular weight is 548.65. CLINICAL PHARMACOLOGY Terbutaline sulfate injection is a beta-adrenergic receptor agonist. _In vitro_ and _in vivo_ pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta -adrenergic receptors. While it is recognized that bet Read the complete document